Assessment Report di Comirnaty di Pfizer/BioNTech, vedi pag. 102 e segg. punto 3.3. Uncertainties and limitations about favourable effects e punto 3.5. Uncertainties and limitations about unfavourable effects
Assessment Report Comirnaty di Pfizer/BioNTec
wordpressadmin2022-03-09T17:16:51+01:009 Marzo, 2022|Covid-19, Libertà e diritti, Trasparenza|0 Commenti
Scrivi un commento